Global Medical REIT(GMRE)

Search documents
Global Medical REIT(GMRE) - 2025 Q1 - Quarterly Report
2025-05-08 20:05
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________. Commission file number: 001-37815 Global Medical REIT Inc. (Exact name of registrant as specified in its charter) | Maryland ...
Global Medical REIT(GMRE) - 2025 Q1 - Earnings Call Transcript
2025-05-08 14:00
Global Medical REIT (GMRE) Q1 2025 Earnings Call May 08, 2025 09:00 AM ET Speaker0 Greetings, and welcome to the Global Medical REIT First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steve Sweatt, Investor Relations. Thank you, sir. You may begin. Speaker1 Thank you. Good mor ...
Global Medical REIT(GMRE) - 2025 Q1 - Earnings Call Presentation
2025-05-08 13:36
Atrium Health – Winston-Salem, NC FIRST QUARTER 2025 EARNINGS SUPPLEMENTAL www.globalmedicalreit.com NYSE: GMRE TABLE OF CONTENTS Legent Hospital for Special Surgery – Plano, TX | Company Overview | 3 | | --- | --- | | Select Quarterly Financial Data | 6 | | Business Summary | 7 | | Acquisitions / Dispositions | 8 | | Portfolio Summary | 9 | | Key Tenants | 12 | | Debt and Hedging Summary | 13 | | Total Capitalization and Equity Summary | 15 | | Sustainability Summary | 16 | | Condensed Consolidated | 17 | ...
Global Medical REIT (GMRE) Q1 FFO Meet Estimates
ZACKS· 2025-05-08 00:25
Global Medical REIT (GMRE) came out with quarterly funds from operations (FFO) of $0.22 per share, in line with the Zacks Consensus Estimate. This compares to FFO of $0.23 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this real estate investment trust would post FFO of $0.22 per share when it actually produced FFO of $0.22, delivering no surprise.Over the last four quarters, the company has not been able to surpass consensus FFO estimates.Global ...
Global Medical REIT(GMRE) - 2025 Q1 - Quarterly Results
2025-05-07 21:00
Exhibit 99.1 First Quarter 2025 and Other Highlights 1 · Net income attributable to common stockholders was $2.1 million, or $0.03 per diluted share, as compared to $0.8 million, or $0.01 per diluted share, in the comparable prior year period. · Funds from operations attributable to common stockholders and noncontrolling interest ("FFO") of $14.8 million, or $0.20 per share and unit, as compared to $14.9 million, or $0.21 per share and unit, in the comparable prior year period. · Adjusted funds from operati ...
Global Medical REIT(GMRE) - 2024 Q4 - Annual Report
2025-02-28 21:05
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-37815 Global Medical REIT Inc. (Exact name of registrant as specified in its charter) | Maryland ...
Global Medical REIT(GMRE) - 2024 Q4 - Earnings Call Transcript
2025-02-28 16:20
Global Medical REIT Inc. (NYSE:GMRE) Q4 2024 Earnings Conference Call February 28, 2025 9:00 AM ET Company Participants Stephen Swett - Investor Relations Jeff Busch - Chief Executive Officer Alfonzo Leon - Chief Investment Officer Bob Kiernan - Chief Financial Officer Conference Call Participants Juan Sanabria - BMO Capital Markets Austin Wurschmidt - KeyBanc Capital Markets Gaurav Mehta - Alliance Global Partners Wes Golladay - Baird Rob Stevenson - Janney Montgomery Scott Operator Greetings, and welcome ...
Global Medical REIT(GMRE) - 2024 Q4 - Earnings Call Presentation
2025-02-28 13:35
Atrium Health – Winston-Salem, NC FOURTH QUARTER 2024 EARNINGS SUPPLEMENTAL www.globalmedicalreit.com NYSE: GMRE TABLE OF CONTENTS Legent Hospital for Special Surgery – Plano, TX | Company Overview | 3 | | --- | --- | | Select Quarterly Financial Data | 6 | | Business Summary | 7 | | Acquisitions / Dispositions | 8 | | Portfolio Summary | 9 | | Key Tenants | 12 | | Debt and Hedging Summary | 13 | | Total Capitalization and Equity | 15 | | Summary | | | Sustainability Summary | 16 | | Condensed Consolidated ...
Global Medical REIT(GMRE) - 2024 Q4 - Annual Results
2025-02-27 22:12
Financial Performance - Net income attributable to common stockholders for Q4 2024 was $1.4 million, or $0.02 per diluted share, compared to a net loss of $0.8 million, or $0.01 per diluted share in Q4 2023[5]. - Total revenue for Q4 2024 was $35,157, an increase of 6.3% compared to $32,962 in Q4 2023[47]. - Net income for the twelve months ended December 31, 2024, was $6,692, a decrease of 69.2% from $21,734 in 2023[49]. - The company reported a gain on the sale of investment properties of $5,765 in Q4 2024, compared to no gain in Q4 2023[49]. - Adjusted EBITDAre for Q4 2024 was $25,095, an increase of 4.1% compared to $24,110 in Q4 2023[51]. Funds from Operations - Funds from Operations (FFO) for Q4 2024 was $11.1 million, or $0.15 per share, down from $13.3 million, or $0.19 per share in the prior year[11]. - Funds from Operations (FFO) attributable to common stockholders for Q4 2024 was $11,051, down from $13,307 in Q4 2023, representing a decrease of 16.9%[49]. - Adjusted Funds from Operations (AFFO) for the full year 2024 was $15.8 million, or $0.22 per share, compared to $15.9 million, or $0.23 per share in 2023[7]. - The company provided 2025 AFFO guidance of $0.89 to $0.93 per share[23]. Acquisitions and Investments - The company completed the acquisition of a 15-property portfolio for $80.3 million, with an annualized base rent of $6.4 million[12]. - The company entered into a joint venture with Heitman, generating $35.2 million in gross proceeds from the sale of two assets[15]. Portfolio and Occupancy - The portfolio leased occupancy was 96.4% as of December 31, 2024, with an annualized base rent of $110 million[17]. - The annualized base rent methodology produces an annualized amount as of a point in time but does not account for future contractual rental rate increases, leasing activity, or lease expirations[38]. Debt and Equity - Total debt outstanding as of December 31, 2024, was $646.1 million, with a leverage ratio of 44.8%[19]. - The company’s total liabilities increased to $700,570,000 in 2024 from $661,886,000 in 2023[42]. - The company’s total equity decreased to $555,916,000 in 2024 from $605,814,000 in 2023[42]. - The company raised $12 million through the issuance of 1.2 million shares at an average price of $9.95 per share during 2024[20]. Cash and Dividends - A cash dividend of $0.21 per share was declared for Q1 2025, payable on April 9, 2025[21]. - Cash and cash equivalents increased to $6,815,000 in 2024 from $1,278,000 in 2023[42]. Other Financial Metrics - The company's accumulated deficit increased to $(293,736,000) in 2024 from $(238,984,000) in 2023[42]. - The weighted average shares outstanding for basic and diluted shares increased to 66,838 in Q4 2024 from 65,565 in Q4 2023[49]. - The company incurred transaction expenses of $155 in Q4 2024, compared to $44 in Q4 2023[49].
Global Medical REIT(GMRE) - 2024 Q3 - Quarterly Report
2024-11-07 21:06
Ownership and Structure - As of September 30, 2024, the company owned 92.51% of the outstanding common operating partnership units of its Operating Partnership[122]. Revenue and Income - The company derives revenues primarily from rental and operating expense reimbursement payments, with most leases being medium to long-term triple net leases[123]. - Total revenue for the three months ended September 30, 2024, was $34.3 million, a decrease of $1.2 million compared to $35.5 million in the same period in 2023[155]. - Rental revenue for the three months ended September 30, 2024, was $34.175 million, down from $35.487 million in 2023, representing a decrease of approximately 3.7%[157]. - Net income for the three months ended September 30, 2024, was $3.391 million, compared to $4.833 million in the same period in 2023, a decrease of 29.9%[157]. - Total revenue for the nine months ended September 30, 2024 was $103.6 million, a decrease of $4.5 million compared to $108.1 million for the same period in 2023[169]. - Net income for the three months ended September 30, 2024, was $3.4 million, down from $4.8 million for the same period in 2023, a decrease of $1.4 million[167]. Funds from Operations - FFO attributable to common stockholders for the three months ended September 30, 2024, was $0.19 per share, down from $0.22 per share in 2023[1]. - AFFO attributable to common stockholders for the three months ended September 30, 2024, was $0.22 per share, compared to $0.23 per share in 2023[1]. - Funds from operations (FFO) attributable to common stockholders for the three months ended September 30, 2024 was $13.7 million, compared to $15.3 million for the same period in 2023[200]. - Adjusted funds from operations (AFFO) attributable to common stockholders for the three months ended September 30, 2024 was $15.3 million, compared to $16.5 million for the same period in 2023[203]. Debt and Financing - As of September 30, 2024, total debt was $628.875 million, with a weighted average interest rate of 3.79%[139]. - During the nine months ended September 30, 2024, the company borrowed $82.8 million under the Credit Facility, resulting in a net amount borrowed of $27.4 million[145]. - Net borrowings on the Credit Facility increased total liabilities to $678.0 million as of September 30, 2024, compared to $661.9 million as of December 31, 2023[182]. - The weighted average interest rate of debt for the nine months ended September 30, 2024 was 3.93%, down from 4.22% for the same period in 2023[175]. - As of September 30, 2024, total fixed debt amounted to $514.5 million with a weighted average interest rate of 3.18%[194]. - The company had unutilized borrowing capacity under the Credit Facility of $221 million as of November 5, 2024[190]. - The company complied with all financial and non-financial covenants under the Credit Facility as of September 30, 2024[192]. - The maximum consolidated unsecured leverage ratio required under the Credit Facility is less than 60%[192]. - The weighted average maturity of the company's fixed debt was 2.1 years as of September 30, 2024[194]. Operating Expenses - Operating expenses for the three months ended September 30, 2024 were $7.4 million, an increase of $0.2 million compared to $7.2 million for the same period in 2023[159]. - General and administrative expenses for the nine months ended September 30, 2024 were $13.4 million, an increase of $0.8 million from $12.6 million in the same period in 2023[170]. - Interest expense for the nine months ended September 30, 2024 was $21.1 million, a decrease of $2.8 million from $23.9 million in the same period in 2023[174]. - Interest expense for the three months ended September 30, 2024, was $7.236 million, slightly higher than $7.170 million in the same period last year, indicating an increase of approximately 0.9%[205]. Acquisitions and Investments - The company completed the acquisition of a 15-property portfolio for a total purchase price of $80.3 million, with an aggregate annualized base rent of $6.4 million[141]. - The company completed five acquisitions and three property sales during the nine months ended September 30, 2024[180]. - The company reported a total investment in real estate of $1.436 billion as of September 30, 2024, with 4.8 million net leasable square feet[140]. Cash Flow - Net cash provided by operating activities for the nine months ended September 30, 2024 was $49.5 million, a decrease from $50.3 million in the same period of 2023[195]. - Net cash used in investing activities for the nine months ended September 30, 2024 was $26.4 million, compared to net cash provided of $70.7 million in the same period of 2023[196]. - Net cash used in financing activities for the nine months ended September 30, 2024 was $22.0 million, down from $127.9 million in the same period of 2023[197]. Economic Environment - The Federal Reserve increased the target range for the Federal Funds Rate from 0.25% – 0.50% in early 2022 to 5.25% – 5.50% as of August 2024, impacting borrowing costs[132]. - In September 2024, the Federal Reserve lowered the target range for the Federal Funds Rate by 0.50% to 4.75% - 5.00%, marking the first rate reduction in four years[133]. - The one-month term Secured Overnight Financing Rate (SOFR) decreased to 4.85% as of September 30, 2024, following the Fed's rate cut[134]. - Healthcare wage inflation remains a concern, with increased labor costs for healthcare systems due to reliance on higher-cost contract nursing labor[136]. Corporate Strategy and Sustainability - The company’s strategy includes investing in off-campus medical outpatient buildings and small to mid-sized healthcare facilities in secondary markets[124]. - The company is focused on corporate sustainability and social responsibility, integrating ESG practices into its operations[126]. - The company continues to explore ways to mitigate climate risk in its acquisition strategy and asset management[130]. - The company aims to provide stockholders with reliable dividends and stock price appreciation through its investment strategy[124]. Risk Management and Controls - The company maintains effective disclosure controls and procedures as of September 30, 2024, ensuring timely reporting of required information[212]. - There were no changes to the internal control over financial reporting during the most recently completed fiscal quarter that materially affected its effectiveness[214]. - The company is not involved in any pending legal proceedings that would materially affect its financial condition or results of operations[215]. - Management does not expect that the disclosure controls and procedures will prevent all errors and fraud, acknowledging inherent limitations in control systems[213]. - The company may enter into additional derivative financial instruments to mitigate interest rate risk on future borrowings, without engaging in speculative transactions[210]. Interest Rate Sensitivity - As of September 30, 2024, the company had $119.8 million of unhedged borrowings outstanding under the Revolver, with a variable interest rate of 4.85%[208]. - If SOFR increases by 100 basis points, the company's cash flow would decrease by approximately $1.2 million annually, while a decrease of 100 basis points would increase cash flow by the same amount[208].